The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 232-247

  De Assis, Leonardo Vinícius Monteiro ^b,c   Locatelli, Jamille ^b,c   Isoldi, Mauro César ^a,b,c  

^a Institute of Exact and Biological Sciences   (Brazil)

^b Laboratory of Hypertension   (Brazil)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Erionite SV40; Genes and pathways; Malignant Mesothelioma; NF2; PI3K AKT

Indexed keywords

ASBESTOS; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMATOSIS TYPE 2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P14; RAF PROTEIN; RAS PROTEIN; SMOOTHENED PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CANCER GENE THERAPY; CARCINOGENESIS; DISEASE ASSOCIATION; DNA METHYLATION; GENE FUNCTION; GENETIC ASSOCIATION; HIPPO PATHWAY; HUMAN; LATS2 GENE; MALIGNANT MESOTHELIOMA; MERLIN HIPPO PATHWAY; NF2 GENE; NONHUMAN; P14 GENE; P16 INK4A GENE; PRIORITY JOURNAL; PROTEIN TARGETING; PTCH1 GENE; REVIEW; SALVADOR GENE; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; SMO GENE; SUFU GENE; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

ERIONITE/SV40; GENES AND PATHWAYS; MALIGNANT MESOTHELIOMA; NF2; P16(INK4A)/P(14ARF); PI3K/AKT;

ASBESTOS; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; ZEOLITES;

EID: 84894044731     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.01.008     Document Type: Review

References (252)

1. Tan C., Treasure T. Mesothelioma: time to take stock. J. R. Soc. Med. 2005, 98:455-458.
2. Becklake M.R., Bagatin E., Neder J.A. Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century. Int. J. Tuberc. Lung Dis. 2007, 11:356-369.
3. Mott F.E. Mesothelioma: a review. Ochsner J. 2012, 12:70-79.
4. Fennell D.A. Genetics and molecular biology of mesothelioma. Malignant Mesothelioma 2012, vol. 189:149-167. Springer, Berlin Heidelberg.
5. Yang H., Testa J., Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr. Treat. Options in Oncol. 2008, 9:147-157.
6. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., Legrand C., Bottomley A., Debruyne C., Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005, 23:6881-6889.
7. Wagner J.C., Sleggs C.A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 1960, 17:260-271.
8. ATSDR Public Health Statement for Asbestos 2001.
9. Manfredi J.J., Dong J., Liu W.J., Resnick-Silverman L., Qiao R., Chahinian P., Saric M., Gibbs A.R., Phillips J.I., Murray J., Axten C.W., Nolan R.P., Aaronson S.A. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 2005, 65:2602-2609.
10. Carthew P., Hill R., Edwards R., Lee P. Intrapleural administration of fibres induces mesothelioma in rats in the same relative order of hazard as occurs in man after exposure. Hum. Exp. Toxicol. 1992, 11:530-534.
11. Cheung M., Talarchek J., Schindeler K., Saraiva E., Penney L.S., Ludman M., Testa J.R. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet. 2013, 206:206-210.
12. Yang C.T., You L., Yeh C.C., Chang J.W.C., Zhang F., McCormick F., Jablons D.M. Adenovirus-mediated p14ARF gene transfer in human mesothelioma cells. J. Natl. Cancer Inst. 2000, 92:636-641.
13. Xio S., Li D., Vijg J., Sugarbaker D.J., Corson J.M., Fletcher J.A. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995, 11:511-515.
14. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 2005, 49:S95-S98. (Amsterdam, Netherlands).
15. Jean D., Daubriac J., Le Pimpec-Barthes F.o., Galateau-Salle F.o., Jaurand M.C. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch. Pathol. Lab. Med. 2012, 136:277-293.
16. Lee K.P., Lee J.H., Kim T.S., Kim T.H., Park H.D., Byun J.S., Kim M.C., Jeong W.I., Calvisi D.F., Kim J.M., Lim D.S. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc. Natl. Acad. Sci. 2010, 107:8248-8253.
17. Frezza C., Martins C.P. From tumor prevention to therapy: empowering p53 to fight back. Drug Resist. Updat. 2012, 15:258-267.
18. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2009, 101:1-6.
19. Bahnassy A.A., Zekri A.-R.N., Abou-Bakr A.A., El-Deftar M.M., El-Bastawisy A., Sakr M.A., El-sherif G.M., Gaafar R.M. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. Exp. Mol. Pathol. 2012, 93:154-161.
20. O'Kane S.L., Pound R.J., Campbell A., Chaudhuri N., Lind M.J., Cawkwell L. Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol. 2006, 45:449-453.
21. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273:13375-13378.
22. Altomare D.A., You H., Xiao G.H., Ramos-Nino M.E., Skele K.L., De Rienzo A., Jhanwar S.C., Mossman B.T., Kane A.B., Testa J.R. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24:6080-6089.
23. Wilson S.M., Barbone D., Yang T.-M., Jablons D.M., Bueno R., Sugarbaker D.J., Nishimura S.L., Gordon G.J., Broaddus V.C. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am. J. Respir. Cell Mol. Biol. 2008, 39:576-583.
24. Carbone M., Ferris L., Baumann F., Napolitano A., Lum C., Flores E., Gaudino G., Powers A., Bryant-Greenwood P., Krausz T., Hyjek E., Tate R., Friedberg J., Weigel T., Pass H., Yang H. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med. 2012, 10:179.
25. Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011, 71:873-883.
26. Suzuki Y., Murakami H., Kawaguchi K., Tanigushi T., Fujii M., Shinjo K., Kondo Y., Osada H., Shimokata K., Horio Y., Hasegawa Y., Hida T., Sekido Y. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol. Med. Rep. 2009, 2:181-188.
27. Lee A.Y., Raz D.J., He B., Jablons D.M. Update on the molecular biology of malignant mesothelioma. Cancer 2007, 109:1454-1461.
28. Edwards J.G., Swinson D.E.B., Jones J.L., Waller D.A., O'Byrne K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54:399-407. (Amsterdam, Netherlands).
29. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
30. Strizzi L., Catalano A., Vianale G., Orecchia S., Casalini A., Tassi G., Puntoni R., Mutti L., Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 2001, 193:468-475.
31. Kindler H.L. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004, 45:S125-S127. (Amsterdam, Netherlands).
32. Kratzke R.A., Otterson G.A., Lincoln C.E., Ewing S., Oie H., Geradts J., Kaye F.J. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Natl. Cancer Inst. 1995, 87:1870-1875.
33. Lowe S.W., Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 2003, 13:77-83.
34. Segers K., Ramael M., Singh S.K., Marck E., Weyler J., Meerbeeck J., Vermeire P. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch. 1994, 424:631-634.
35. Soini Y., Kinnula V., Kaarteenaho-Wiik R., Kurttila E., Linnainmaa K., Pääkkö P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin. Cancer Res. 1999, 5:3508-3515.
36. Hopkins-Donaldson S., Cathomas R., Simões-Wüst A.P., Kurtz S., Belyanskya L., Stahel R.A., Zangemeister-Wittke U. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int. J. Cancer 2003, 106:160-166.
37. Yu F.-X., Guan K.-L. The Hippo pathway: regulators and regulations. Genes Dev. 2013, 27:355-371.
38. Mizuno T., Murakami H., Fujii M., Ishiguro F., Tanaka I., Kondo Y., Akatsuka S., Toyokuni S., Yokoi K., Osada H., Sekido Y. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 2012, 31:5117-5122.
39. Fujii M., Toyoda T., Nakanishi H., Yatabe Y., Sato A., Matsudaira Y., Ito H., Murakami H., Kondo Y., Kondo E., Hida T., Tsujimura T., Osada H., Sekido Y. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med. 2012, 209:479-494.
40. Saito-Diaz K., Chen T., Wang X., Thorne C., Wallace H., Page-McCaw A., Lee E. The way Wnt works: components and mechanism. Growth Factors 2013, 31:1-31.
41. 2-catenin. Cancer Res. 2003, 63:4547-4551.
42. de Assis L.V., Isoldi M.C. The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumor Biol. 2013, 1-13.
43. Kroczynska B., Cutrone R., Bocchetta M., Yang H., Elmishad A.G., Vacek P., Ramos-Nino M., Mossman B.T., Pass H.I., Carbone M. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc. Natl. Acad. Sci. 2006, 103:14128-14133.
44. Carbone M., Pass H.I., Miele L., Bocchetta M. New developments about the association of SV40 with human mesothelioma. Oncogene 2003, 22:5173-5180.
45. Shivapurkar N., Wiethege T., Wistuba I.I., Salomon E., Milchgrub S., Muller K.M., Churg A., Pass H., Gazdar A.F. Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J. Cell. Biochem. 1999, 76:181-188.
46. Lopez-Rios F., Illei P.B., Rusch V., Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004, 364:1157-1166.
47. Comar M., Zanotta N., Pesel G., Visconti P., Maestri I., Rinaldi R., Crovella S., Cortale M., De Zotti R., Bovenzi M. Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy. Tumori 2012, 98:210-214.
48. Hubner R., Van Marck E. Reappraisal of the strong association between simian virus 40 and human malignant mesothelioma of the pleura (Belgium). Cancer Causes Control 2002, 13:121-129.
49. Eom M., Abdul-Ghafar J., Park S., Han J., Hong S., Kwon K., Ko E., Kim L., Kim W., Ha S., Lee K., Lee C., Yoon H., Choi Y., Chung M., Jung S. No detection of simian virus 40 in malignant mesothelioma in Korea. Kor. J. Pathol. 2013, 47:124-129.
50. Hmeljak J., Kern I., Cör A. No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia. Tumori 2010, 96:667-673.
51. Qi F., Carbone M., Yang H., Gaudino G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev. Respir. Med. 2012, 5:683-697.
52. Cicala C., Pompetti F., Carbone M. SV40 induces mesotheliomas in hamsters. Am. J. Pathol. 1993, 142:1524-1533.
53. Robinson C., van Bruggen I., Segal A., Dunham M., Sherwood A., Koentgen F., Robinson B.W.S., Lake R.A. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 2006, 66:10786-10794.
54. Cleaver A.L., Bhamidipaty K., Wylie B., Connor T., Robinson C., Robinson B.W., Mutsaers S.E., Lake R.A. Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance. Carcinogenesis 2013, 35(2):407-414.
55. Bocchetta M., Miele L., Pass H., Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene 2003, 22:81-89.
56. Bocchetta M., Eliasz S., De Marco M.A., Rudzinski J., Zhang L., Carbone M. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res. 2008, 68:1022-1029.
57. Catalano A., Romano M., Martinotti S., Procopio A. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene 2002, 25:2896-2900.
58. Foddis R., De Rienzo A., Broccoli D., Bocchetta M., Stekala E., Rizzo P., Tosolini A., Grobelny J., Jhanwar S., Pass H., Testa J., Carbone M. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 2002, 21:1434-1442.
59. Pietruska J.R., Kane A.B. SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res. 2007, 67:3637-3645.
60. Rake C., Gilham C., Hatch J., Darnton A., Hodgson J., Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br. J. Cancer 2009, 100:1175-1183.
61. Coffin D.L., Cook P.M., Creason J.P. Relative mesothelioma induction in rats by mineral fibers: comparison with residual pulmonary mineral fiber number and epidemiology. Inhal. Toxicol. 1992, 4:273-300.
62. Sebastien P., Gaudichet A., Bignon J., Baris Y. Zeolite bodies in human lungs from Turkey. Lab. Invest. 1981, 44:420-425.
63. Baris I., Simonato L., Artvinli M., Pooley F., Saracci R., Skidmore J., Wagner C. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int. J. Cancer 1987, 39:10-17.
64. Dumortier P., Coplü L., Broucke I., Emri S., Selcuk T., de Maertelaer V., De Vuyst P., Baris I. Erionite bodies and fibres in bronchoalveolar lavage fluid (BALF) of residents from Tuzköy, Cappadocia, Turkey. Occup. Environ. Med. 2001, 58:261-266.
65. Ilgren E.B., Pooley F.D., Larragoitia J.C., Talamantes M., Navarrete G.L., Krauss E., Breña A.F. First confirmed erionite related mesothelioma in North America. Indoor Built Environ. 2008, 17:567-568.
66. Kliment C., Clemens K., Oury T. North American erionite-associated mesothelioma with pleural plaques and pulmonary fibrosis: a case report. Int. J. Clin. Exp. Pathol. 2009, 2:407-410.
67. Carbone M., Baris Y.I., Bertino P., Brass B., Comertpay S., Dogan A.U., Gaudino G., Jube S., Kanodia S., Partridge C.R., Pass H.I., Rivera Z.S., Steele I., Tuncer M., Way S., Yang H., Miller A. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc. Natl. Acad. Sci. 2011, 108(33):13611-13623.
68. Jube S., Rivera Z.S., Bianchi M.E., Powers A., Wang E., Pagano I., Pass H.I., Gaudino G., Carbone M., Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012, 72:3290-3301.
69. Carbone M., Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin. Cancer Res. 2013, 18:598-604.
70. Wang Y., Faux S., Hallden G., Kirn D., Houghton C., Lemoine N., Patrick G. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int. J. Oncol. 2004, 25:173-180.
71. Hillegass J., Miller J., MacPherson M., Westbom C., Sayan M., Thompson J., Macura S., Perkins T., Beuschel S., Alexeeva V., Pass H., Steele C., Mossman B., Shukla A. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol. 2013, C7-39(10):1-14.
72. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1998, 1378:F115-F177.
73. Thillainadesan G., Chitilian J.M., Isovic M., Ablack J.N., Mymryk J.S., Tini M., Torchia J. TGF-beta-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. Mol. Cell 2012, 46:636-649.
74. Krimpenfort P., Ijpenberg A., Song J.Y., van der Valk M., Nawijn M., Zevenhoven J., Berns A. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007, 448:943-946.
75. Berggren P., Kumar R., Sakano S., Hemminki L., Wada T., Steineck G., Adolfsson J., Larsson P., Norming U., Wijkström H., Hemminki K. Detecting homozygous deletions in the CDKN2A(p16INK4a)/ARF(p14ARF) gene in urinary bladder cancer using real-time quantitative PCR. Clin. Cancer Res. 2003, 9:235-242.
76. Chang L.L., Yeh W.T., Yang S.Y., Wu W.J., Huang C.H. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J. Urol. 2003, 170:595-600.
77. Brown V.L., Harwood C.A., Crook T., Cronin J.G., Kelsell D.P., Proby C.M. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J. Invest. Dermatol. 2004, 122:1284-1292.
78. Wang J.L., Zheng B.Y., Li X.D., Nokelainen K., Angstrom T., Lindstrom M.S., Wallin K.L. p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. Mod. Pathol. 2005, 18:629-637.
79. Cheng J.Q., Jhanwar S.C., Klein W.M., Bell D.W., Lee W.-C., Altomare D.A., Nobori T., Olopade O.I., Buckler A.J., Testa J.R. p16 Alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994, 54:5547-5551.
80. Illei P.B., Rusch V.W., Zakowski M.F., Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. 2003, 9:2108-2113.
81. Onofre F.B., Onofre A.S., Pomjanski N., Buckstegge B., Grote H.J., Bocking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 2008, 114:204-215.
82. Takeda M., Kasai T., Enomoto Y., Takano M., Morita K., Kadota E., Iizuka N., Maruyama H., Nonomura A. Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. J. Clin. Pathol. 2012, 65:77-82.
83. Chiosea S., Krasinskas A., Cagle P.T., Mitchell K.A., Zander D.S., Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod. Pathol. 2008, 21:742-747.
84. 2 and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006, 54:109-116.
85. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
86. Sharpless N.E., Bardeesy N., Lee K.H., Carrasco D., Castrillon D.H., Aguirre A.J., Wu E.A., Horner J.W., DePinho R.A. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001, 413:86-91.
87. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
88. Altomare D.A., Menges C.W., Pei J., Zhang L., Skele-Stump K.L., Carbone M., Kane A.B., Testa J.R. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3420-3425.
89. Altomare D.A., Menges C.W., Xu J., Pei J., Zhang L., Tadevosyan A., Neumann-Domer E., Liu Z., Carbone M., Chudoba I., Klein-Szanto A.J., Testa J.R. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One 2011, 6:e18828.
90. Frizelle S., Grim J., Zhou J., Gupta P., Curiel D., Geradts J., Kratzke R. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998, 16:3087-3095.
91. Frizelle S., Rubins J., Zhou J., Curiel D., Kratzke R. Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther. 2000, 7:1421-1425.
92. Yang C., You L., Lin Y., Lin C., McCormick F., Jablons D. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res. 2003, 23:33-38.
93. Tada Y., Shimada H., Hiroshima K., Tagawa M. A potential therapeutic strategy for malignant mesothelioma with gene medicine. Biomed. Res. Int. 2013, 2013:8.
94. Evans D.G.R. Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet. Med. 2009, 11:599.
95. Sekido Y., Pass H.I., Bader S., Mew D.J.Y., Christman M.F., Gazdar A.F., Minna J.D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995, 55:1227-1231.
96. Bianchi A.B., Mitsunaga S.I., Cheng J.Q., Klein W.M., Jhanwar S.C., Seizinger B., Kley N., Klein-Szanto A.J., Testa J.R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:10854-10858.
97. Andujar P., Pairon J.C., Renier A., Descatha A., Hysi I., Abd-Alsamad I., Billon-Galland M.A., Blons H.l.n., Clin B.n.d., Danel C., Debrosse D., Galateau-Sallé F.o., Housset B., Laurent-Puig P., Le Pimpec-Barthes F.o., Letourneux M., Monnet I., Régnard J.F.o., Validire P., Zucman-Rossi J., Jaurand M.C., Jean D. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis 2013, 28:323-331.
98. Nemoto H., Tate G., Kishimoto K., Saito M., Shirahata A., Umemoto T., Matsubara T., Goto T., Mizukami H., Kigawa G., Mitsuya T., Hibi K. Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum. Cancer Genet. 2012, 205:594-598.
99. Guled M., Lahti L., Lindholm P.M., Salmenkivi K., Bagwan I., Nicholson A.G., Knuutila S. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-a miRNA microarray analysis. Genes Chromosom. Cancer 2009, 48:615-623.
100. Jongsma J., van Montfort E., Vooijs M., Zevenhoven J., Krimpenfort P., van der Valk M., van de Vijver M., Berns A. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008, 13:261-271.
101. Ikeda K., Saeki Y., Gonzalez-Agosti C., Ramesh V., Chiocca E.A. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J. Neurosurg. 1999, 91:85-92.
102. Schulze K.M.M., Hanemann C.O., Müller H.W., Hanenberg H. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum. Mol. Genet. 2002, 11:69-76.
103. Fraenzer J., Pan H., Minimo L.J., Smith G., Knauer D., Hung G. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int. J. Oncol. 2003, 2003:1493-1500.
104. Morales F.C., Molina J.R., Hayashi Y., Georgescu M.-M. Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro-Oncology 2010, 12:528-539.
105. Poulikakos P., Xiao G., Gallagher R., Jablonski S., Jhanwar S., Testa J. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006, 25:5960-5980.
106. Xiao G.H., Gallagher R., Shetler J., Skele K., Altomare D.A., Pestell R.G., Jhanwar S., Testa J.R. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol. Cell. Biol. 2005, 25:2384-2394.
107. Roushdy-Hammady I., Siegel J., Emri S., Testa J.R., Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001, 357:444-445.
108. Dogan A.U., Baris Y.I., Dogan M., Emri S., Steele I., Elmishad A.G., Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006, 66:5063-5068.
109. Metintas M., Hillerdal G., Metintas S., Dumortier P. Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors. Arch. Environ. Occup. Health 2010, 65:86-93.
110. Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J., Dogan A.U., Pass H.I., Trusa S., Hesdorffer M., Nasu M., Powers A., Rivera Z., Comertpay S., Tanji M., Gaudino G., Yang H., Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 2011, 43:1022-1025.
111. Popova T., Hebert L., Jacquemin V., Gad S., Caux-Moncoutier V., Dubois-d Enghien C., Richaudeau B., Renaudin X., Sellers J., Nicolas A., Sastre-Garau X., Desjardins L., Gyapay G., Raynal V., Sinilnikova Olga M., Andrieu N., Manié E., de Pauw A., Gesta P., Bonadona V., Maugard Christine M., Penet C., Avril M.F., Barillot E., Cabaret O., Delattre O., Richard S., Caron O., Benfodda M., Hu H.-H., Soufir N., Bressac-de Paillerets B., Stoppa-Lyonnet D., Stern M.-H. Germline BAP1 mutations predispose to renal cell carcinomas. Am. J. Hum. Genet. 2013, 92:974-980.
112. Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S., Zhou Q., Shen R., Olshen A., Rusch V., Ladanyi M. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 2011, 43:668-672.
113. Yoshikawa Y., Sato A., Tsujimura T., Emi M., Morinaga T., Fukuoka K., Yamada S., Murakami A., Kondo N., Matsumoto S., Okumura Y., Tanaka F., Hasegawa S., Nakano T., Hashimoto-Tamaoki T. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012, 103:868-874.
114. Zauderer M., Bott M., McMillan R., Sima C., Rusch V., Krug L., Ladanyi M. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J. Thorac. Oncol. 2013, 8:1430-1433.
115. Arzt L., Quehenberger F., Halbwedl I., Mairinger T., Popper H. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol. Oncol. Res. 2013, 1-7.
116. Murali R., Wiesner T., Scolyer R. Tumours associated with BAP1 mutations. Pathology 2013, 45:116-126.
117. Pilarski R., Cebulla C.M., Massengill J.B., Rai K., Rich T., Strong L., McGillivray B., Asrat M.-J., Davidorf F.H., Abdel-Rahman M.H. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosom. Cancer 2013, 53(2):177-182.
118. Justice R.W., Zilian O., Woods D.F., Noll M., Bryant P.J. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995, 9:534-546.
119. Yabuta N., Fujii T., Copeland N.G., Gilbert D.J., Jenkins N.A., Nishiguchi H., Endo Y., Toji S., Tanaka H., Nishimune Y., Nojima H. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics 2000, 63:263-270.
120. Chen C.F., Yeh S.H., Chen D.S., Chen P.J., Jou Y.S. Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. Genes Chromosom. Cancer 2005, 44:320-328.
121. Aylon Y., Michael D., Shmueli A., Yabuta N., Nojima H., Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 2006, 20:2687-2700.
122. Aylon Y., Ofir-Rosenfeld Y., Yabuta N., Lapi E., Nojima H., Lu X., Oren M. The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev. 2010, 24:2420-2429.
123. Visser S., Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010, 9:3922-3933.
124. Christensen B.C., Houseman E.A., Godleski J.J., Marsit C.J., Longacker J.L., Roelofs C.R., Karagas M.R., Wrensch M.R., Yeh R.-F., Nelson H.H., Wiemels J.L., Zheng S., Wiencke J.K., Bueno R., Sugarbaker D.J., Kelsey K.T. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 2009, 69:227-234.
125. Goto Y., Shinjo K., Kondo Y., Shen L., Toyota M., Suzuki H., Gao W., An B., Fujii M., Murakami H., Osada H., Taniguchi T., Usami N., Kondo M., Hasegawa Y., Shimokata K., Matsuo K., Hida T., Fujimoto N., Kishimoto T., Issa J.-P.J., Sekido Y. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009, 69:9073-9082.
126. Fischer J.R., Ohnmacht U., Rieger N., Zemaitis M., Stoffregen C., Kostrzewa M., Buchholz E., Manegold C., Lahm H. Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006, 54:109-116.
127. Vandermeers F., Neelature Sriramareddy S., Costa C., Hubaux R., Cosse J.-P., Willems L. The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 2013, 81:311-318. (Amsterdam, Netherlands).
128. Ivanov S.V., Goparaju C.M.V., Lopez P., Zavadil J., Toren-Haritan G., Rosenwald S., Hoshen M., Chajut A., Cohen D., Pass H.I. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J. Biol. Chem. 2010, 285:22809-22817.
129. Reid G., Pel M.E., Kirschner M.B., Cheng Y.Y., Mugridge N., Weiss J., Williams M., Wright C., Edelman J.J.B., Vallely M.P., McCaughan B.C., Klebe S., Brahmbhatt H., MacDiarmid J.A., van Zandwijk N. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. 2013, 24(12):3128-3135.
130. Gee G.V., Koestler D.C., Christensen B.C., Sugarbaker D.J., Ugolini D., Ivaldi G.P., Resnick M.B., Houseman E.A., Kelsey K.T., Marsit C.J. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int. J. Cancer 2010, 127:2859-2869.
131. Kirschner M.B., Cheng Y.Y., Badrian B., Kao S.C., Creaney J., Edelman J.J., Armstrong N.J., Vallely M.P., Musk A.W., Robinson B.W., McCaughan B.C., Klebe S., Mutsaers S.E., van Zandwijk N., Reid G. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 2012, 7:1184-1191.
132. Muraoka T., Soh J., Toyooka S., Aoe K., Fujimoto N., Hashida S., Maki Y., Tanaka N., Shien K., Furukawa M., Yamamoto H., Asano H., Tsukuda K., Kishimoto T., Otsuki T., Miyoshi S. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer 2013, 82(3):485-490.
133. Cioce M., Ganci F., Canu V., Sacconi A., Mori F., Canino C., Korita E., Casini B., Alessandrini G., Cambria A., Carosi M.A., Blandino R., Panebianco V., Facciolo F., Visca P., Volinia S., Muti P., Strano S., Croce C.M., Pass H.I., Blandino G. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 2013, in press, (Epub ahead of print).
134. Tapon N., Harvey K.F., Bell D.W., Wahrer D.C.R., Schiripo T.A., Haber D.A., Hariharan I.K. salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002, 110:467-478.
135. Lu L., Li Y., Kim S.M., Bossuyt W., Liu P., Qiu Q., Wang Y., Halder G., Finegold M.J., Lee J.-S., Johnson R.L. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. 2010, 107:1437-1442.
136. Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y., Hasegawa Y., Bader S., Gazdar A., Minna J., Hida T., Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001, 20:4249-4257.
137. Usami N., Sekido Y., Maeda O., Yamamoto K., Minna J., Hasegawa Y., Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., S.K. Beta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion. Oncogene 2003, 22:7923-7930.
138. You M., Varona-Santos J., Singh S., Robbins D.J., Savaraj N., Nguyen D.M. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J. Thorac. Cardiovasc. Surg. 2013, 147(1):508-516.
139. Lim C.B., Prêle C.M., Cheah H.M., Cheng Y.Y., Klebe S., Reid G., Watkins D.N., Baltic S., Thompson P.J., Mutsaers S.E. Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. PLoS One 2013, 8:e66685.
140. Klorin G., Rozenblum E., Glebov O., Walker R.L., Park Y., Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V. Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines. Cancer Genet. 2013, 206:191-205.
141. Savvidis C., Koutsilieris M. Circadian rhythm disruption in cancer biology. Mol. Med. 2012, 18:1249-1260.
142. Stevens R.G. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 2005, 16:254-258.
143. Giacchetti S., Bjarnason G., Garufi C., Genet D., Iacobelli S., Tampellini M., Smaaland R., Focan C., Coudert B., Humblet Y., Canon J.L., Adenis A., Re G.L., Carvalho C., Schueller J., Anciaux N., Lentz M.A., Baron B.t., Gorlia T., Lévi F. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J. Clin. Oncol. 2006, 24:3562-3569.
144. Røe O.D., Anderssen E., Helge E., Pettersen C.H., Olsen K.S., Sandeck H., Haaverstad R., Lundgren S., Larsson E. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One 2009, 4:e6554.
145. Elshazley M., Sato M., Hase T., Yamashita R., Yoshida K., Toyokuni S., Ishiguro F., Osada H., Sekido Y., Yokoi K., Usami N., Shames D.S., Kondo M., Gazdar A.F., Minna J.D., Hasegawa Y. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. Int. J. Cancer 2012, 131:2820-2831.
146. Brevet M., Shimizu S., Bott M.J., Shukla N., Zhou Q., Olshen A.B., Rusch V., Ladanyi M. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J. Thorac. Oncol. 2011, 6:864-874.
147. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
148. Agarwal V., Lind M.J., Cawkwell L. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treat. Rev. 2011, 37:533-542.
149. Kothmaier H., Quehenberger F., Halbwedl I., Morbini P., Demirag F., Zeren H., Comin C.E., Murer B., Cagle P.T., Attanoos R., Gibbs A.R., Galateau-Salle F., Popper H.H. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 2008, 63:345-351.
150. Destro A., Ceresoli G.L., Falleni M., Zucali P.A., Morenghi E., Bianchi P., Pellegrini C., Cordani N., Vaira V., Alloisio M., Rizzi A., Bosari S., Roncalli M. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215. (Amsterdam, Netherlands).
151. Govindan R., Kratzke R.A., Herndon J.E., Niehans G.A., Vollmer R., Watson D., Green M.R., Kindler H.L. Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B. Clin. Cancer Res. 2005, 11:2300-2304.
152. Garland L.L., Rankin C., Gandara D.R., Rivkin S.E., Scott K.M., Nagle R.B., Klein-Szanto A.J.P., Testa J.R., Altomare D.A., Borden E.C. Phase II study of Erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study. J. Clin. Oncol. 2007, 25:2406-2413.
153. Linder C., Linder S., Munck-Wikland E., Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res. 1998, 18:2063-2068.
154. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 1999, 189:72-78.
155. Demirag F., UÌ̂nsal E., Yilmaz A., Çağlar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma*. Chest J. 2005, 128:3382-3387.
156. Aoe K., Hiraki A., Tanaka T., Gemba K.-I., Taguchi K., Murakami T., Sueoka N., Kamei T., Ueoka H., Sugi K., Yoshino T., Kishimoto T. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res. 2006, 26:4833-4836.
157. Favoni R.E., Daga A., Malatesta P., Florio T. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br. J. Pharmacol. 2012, 166:532-553.
158. Jackman D.M., Kindler H.L., Yeap B.Y., Fidias P., Salgia R., Lucca J., Morse L.K., Ostler P.A., Johnson B.E., Jänne P.A. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008, 113:808-814.
159. Whitson B.A., Kratzke R.A. Molecular pathways in malignant pleural mesothelioma. Cancer Lett. 2006, 239:183-189.
160. Hoang C.D., D'Cunha J., Kratzke M.G., Casmey C.E., Frizelle S.P., Maddaus M.A., Kratzke R.A. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004, 125:1843-1852.
161. Hoang C.D., Zhang X., Scott P.D., Guillaume T.J., Maddaus M.A., Yee D., Kratzke R.A. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res. 2004, 64:7479-7485.
162. Kalra N., Zhang J., Yu Y., Ho M., Merino M., Cao L., Hassan R. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell. Int. J. Cancer 2012, 131:2143-2152.
163. Pass H.I., Goparaju C., Ivanov S., Donington J., Carbone M., Hoshen M., Cohen D., Chajut A., Rosenwald S., Dan H., Benjamin S., Aharonov R. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010, 70:1916-1924.
164. Busacca S., Germano S., De Cecco L., Rinaldi M., Comoglio F., Favero F., Murer B., Mutti L., Pierotti M., Gaudino G. microRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am. J. Respir. Cell Mol. Biol. 2010, 42:312-319.
165. Thirkettle I., Harvey P., Hasleton P.S., Ball R.Y., Warn R.M. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 2000, 36:522-528.
166. Jagadeeswaran R., Ma P.C., Seiwert T.Y., Jagadeeswaran S., Zumba O., Nallasura V., Ahmed S., Filiberti R., Paganuzzi M., Puntoni R., Kratzke R.A., Gordon G.J., Sugarbaker D.J., Bueno R., Janamanchi V., Bindokas V.P., Kindler H.L., Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006, 66:352-361.
167. Kawaguchi K., Murakami H., Taniguchi T., Fujii M., Kawata S., Fukui T., Kondo Y., Osada H., Usami N., Yokoi K., Ueda Y., Yatabe Y., Ito M., Horio Y., Hida T., Sekido Y. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009, 30:1097-1105.
168. Mukohara T., Civiello G., Davis I.J., Taffaro M.L., Christensen J., Fisher D.E., Johnson B.E., Jänne P.A. Inhibition of the Met receptor in mesothelioma. Clin. Cancer Res. 2005, 11:8122-8130.
169. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W.T., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta, Mol. Cell. Res. 2007, 1773:1263-1284.
170. Díez D., Sánchez-Jiménez F., Ranea J. Evolutionary expansion of the Ras switch regulatory module in eukaryotes. Nucleic Acids Res. 2011, 39(13):5526-5537.
171. Santarpia L., Lippman S.M., El-Naggar A.K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:103-119.
172. Mebratu Y., Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer?. Cell Cycle 2009, 8:1168-1175.
173. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
174. Melo M.d., Gerbase M.W., Curran J., Pache J.C. Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. J. Histochem. Cytochem. 2006, 54:855-861.
175. Vintman L., Nielsen S., Berner A., Reich R., Davidson B. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 2005, 103:2427-2433.
176. Zanella C.L., Posada J., Tritton T.R., Mossman B.T. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. 1996, 56:5334-5338.
177. Cummins A.B., Palmer C., Mossman B.T., Taatjes D.J. Persistent localization of activated extracellular signal-regulated kinases (ERK1/2) is epithelial cell-specific in an inhalation model of asbestosis. Am. J. Pathol. 2003, 162:713-720.
178. Shukla A., Hillegass J.M., MacPherson M.B., Beuschel S.L., Vacek P.M., Butnor K.J., Pass H.I., Carbone M., Testa J.R., Heintz N.H., Mossman B.T. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int. J. Cancer 2011, 129:1075-1086.
179. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17:615-675.
180. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
181. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4:127-150.
182. Chen M., Cassidy A., Gu J., Delclos G.L., Zhen F., Yang H., Hildebrandt M.A., Lin J., Ye Y., Chamberlain R.M., Dinney C.P., Wu X. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 2009, 30:2047-2052.
183. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
184. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
185. Mora A., Komander D., van Aalten D.M., Alessi D.R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 2004, 15:161-170.
186. Ching C.B., Hansel D.E. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest. 2010, 90:1406-1414.
187. Sonenberg N., Gingras A.C. The mRNA 5' cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 1998, 10:268-275.
188. Pullen N., Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997, 410:78-82.
189. Ramos-Nino M.E., Vianale G., Sabo-Attwood T., Mutti L., Porta C., Heintz N., Mossman B.T. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol. Cancer Ther. 2005, 4:835-842.
190. Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004, 23:3172-3179.
191. Chiang G.G., Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13:433-442.
192. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 2003, 22:183-198.
193. Tanno S., Tanno S., Mitsuuchi Y., Altomare D.A., Xiao G.H., Testa J.R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001, 61:589-593.
194. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
195. Liu A.-x., Testa J.R., Hamilton T.C., Jove R., Nicosia S.V., Cheng J.Q. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res. 1998, 58:2973-2977.
196. Actor B., Cobbers J.M., Buschges R., Wolter M., Knobbe C.B., Lichter P., Reifenberger G., Weber R.G. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Gene Chromosome Cancer 2002, 34:416-427.
197. Knobbe C.B., Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003, 13:507-518.
198. Pedrero J.M., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodrigo J.P., Nieto C.S., Gonzalez M.V. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 2005, 114:242-248.
199. Chow L.M., Baker S.J. PTEN function in normal and neoplastic growth. Cancer Lett. 2006, 241:184-196.
200. Kim K.-U., Wilson S.M., Abayasiriwardana K.S., Collins R., Fjellbirkeland L., Xu Z., Jablons D.M., Nishimura S.L., Broaddus V.C. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am. J. Respir. Cell Mol. Biol. 2005, 33:541-548.
201. Mohiuddin I., Cao X., Ozvaran M.K., Zumstein L., Chada S., Smythe W.R. Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation. Ann. Surg. Oncol. 2002, 9:310-316.
202. Cedrés M.A.S., Montero P., Martinez A., Martinez V., Rodríguez-Freixinós D., Torrejon A., Gabaldon M., Salcedo S., y Cajal Ramon, Felip E. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012, 77:192-198. (Amsterdam, Netherlands).
203. Zhao L., Vogt P.K. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 2010, 9:596-600.
204. Vogt P.K., Kang S., Elsliger M.A., Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 2007, 32:342-349.
205. Varghese S., Chen Z., Bartlett D.L., Pingpank J.F., Libutti S.K., Steinberg S.M., Wunderlich J., Alexander H.R. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 2011, 117:361-371.
206. Fennell D.A., Rudd R.M. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol. 2004, 5:354-362.
207. Bedogni B., Welford S.M., Kwan A.C., Ranger-Moore J., Saboda K., Powell M.B. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol. Cancer Ther. 2006, 5:3071-3077.
208. Cole G.W., Alleva A.M., Zuo J.T., Sehgal S.S., Yeow W.-S., Schrump D.S., Nguyen D.M. Suppression of Pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res. 2006, 26:809-821.
209. Barbone D., Yang T.M., Morgan J.R., Gaudino G., Broaddus V.C. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J. Biol. Chem. 2008, 283:13021-13030.
210. Knight Z.A., Shokat K.M. Chemically targeting the PI3K family. Biochem. Soc. Trans. 2007, 35:245-249.
211. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
212. Yang L., Dan H.C., Sun M., Liu Q., Sun X.-m., Feldman R.I., Hamilton A.D., Polokoff M., Nicosia S.V., Herlyn M., Sebti S.M., Cheng J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004, 64:4394-4399.
213. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
214. Leard L.E., Broaddus V.C. Mesothelial cell proliferation and apoptosis. Respirology 2004, 9:292-299.
215. Narasimhan S.R., Yang L., Gerwin B.I., Broaddus V.C. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am. J. Physiol. 1998, 275:L165-L171.
216. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992.
217. Raisova M., Hossini A.M., Eberle J., Riebeling C., Wieder T., Sturm I., Daniel P.T., Orfanos C.E., Geilen C.C. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J. Invest. Dermatol. 2001, 117:333-340.
218. Cao X., Rodarte C., Zhang L., Morgan C.D., Littlejohn J., Smythe W.R. Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol. Ther. 2007, 6:246-252.
219. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
220. Cao X.X., Mohuiddin I., Ece F., McConkey D.J., Smythe W.R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell Mol. Biol. 2001, 25:562-568.
221. Smythe W.R., Mohuiddin I., Ozveran M., Cao X.X. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J. Thorac. Cardiovasc. Surg. 2002, 123:1191-1198.
222. Littlejohn J.E., Cao X., Miller S.D., Ozvaran M.K., Jupiter D., Zhang L., Rodarte C., Smythe W.R. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int. J. Cancer 2008, 123:202-208.
223. Varin E., Denoyelle C., Brotin E., Meryet-FiguiÃr̈re M., Giffard F., Abeilard E., Goux D., Gauduchon P., Icard P., Poulain L. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 2010, 31:984-993.
224. Cao X., Yap J., Newell-Rogers M., Peddaboina C., Jiang W., Papaconstantinou H., Jupitor D., Rai A., Jung K.-Y., Tubin R., Yu W., Vanommeslaeghe K., Wilder P., MacKerell A., Fletcher S., Smythe R. The novel BH3 alpha-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol. Cancer 2013, 12:42.
225. Yuan B.Z., Chapman J.A., Reynolds S.H. Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Transl. Oncol. 2008, 1:129-140.
226. Morrow K.A., Shevde L.A. Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim. Biophys. Acta, Rev. Cancer 2012, 1826:400-406.
227. Tsukita S., Oishi K., Sato N., Sagara J., Kawai A. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol. 1994, 126:391-401.
228. Stamenkovic I., Yu Q. Merlin, a "Magic" linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr. Protein Pept. Sci. 2010, 11:471-484.
229. Rong R., Tang X., Gutmann D.H., Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc. Natl. Acad. Sci. 2004, 101:18200-18205.
230. James M.F., Han S., Polizzano C., Plotkin S.R., Manning B.D., Stemmer-Rachamimov A.O., Gusella J.F., Ramesh V. NF2/Merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell. Biol. 2009, 29:4250-4261.
231. Curto M., Cole B.K., Lallemand D., Liu C.H., McClatchey A.I. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell Biol. 2007, 177:893-903.
232. Thurneysen C., Opitz I., Kurtz S., Weder W., Stahel R.A., Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009, 64:140-147. (Amsterdam, Netherlands).
233. Yokoyama T., Osada H., Murakami H., Tatematsu Y., Taniguchi T., Kondo Y., Yatabe Y., Hasegawa Y., Shimokata K., Horio Y., Hida T., Sekido Y. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008, 29:2139-2146.
234. Logan C.Y., Nusse R. The WNT signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20:781-810.
235. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8:387-398.
236. 2-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17:9-26.
237. Lee A.Y., He B., You L., Dadfarmay S., Xu Z., Mazieres J., Mikami I., McCormick F., Jablons D.M. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004, 23:6672-6676.
238. Batra S., Shi Y., Kuchenbecker K.M., He B., Reguart N., Mikami I., You L., Xu Z., Lin Y.-C., Clément G.v., Jablons D.M. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem. Biophys. Res. Commun. 2006, 342:1228-1232.
239. Kohno H., Amatya V.J., Takeshima Y., Kushitani K., Hattori N., Kohno N., Inai K. Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol. Rep. 2010, 24:423-431.
240. Abutaily A.S., Collins J.E., Roche W.R. Cadherins, catenins and APC in pleural malignant mesothelioma. J. Pathol. 2003, 201:355-362.
241. Anani W., Bruggeman R., Zander D.S. Beta-catenin expression in benign and malignant pleural disorders. Int. J. Clin. Exp. Pathol. 2011, 4:742-747.
242. Fox S.A., Richards A.K., Kusumah I., Perumal V., Bolitho E.M., Mutsaers S.E., Dharmarajan A.M. Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 2013, 440:82-87.
243. Kobayashi M., Huang C.L., Sonobe M., Kikuchi R., Ishikawa M., Kitamura J., Miyahara R., Menju T., Iwakiri S., Itoi K., Yasumizu R., Date H. Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients. Exp. Ther. Med. 2012, 3:952-958.
244. Mazieres J., You L., He B., Xu Z., Twogood S., Lee A.Y., Reguart N., Batra S., Mikami I., Jablons D.M. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int. J. Cancer 2005, 117:326-332.
245. He B., You L., Uematsu K., Xu Z., Lee A.Y., Matsangou M., McCormick F., Jablons D.M. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004, 6:7-14.
246. Dai Y., Bedrossian C.W.M., Michael C.W. The expression pattern of β-catenin in mesothelial proliferative lesions and its diagnostic utilities. Diagn. Cytopathol. 2005, 33:320-324.
247. Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K., Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M., Sekido Y. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 2007, 98:438-446.
248. Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006, 97:387-394.
249. Tochigi N., Attanoos R., Chirieac L.R., Allen T.C., Cagle P.T., Dacic S. p16 deletion in sarcomatoid tumors of the lung and pleura. Arch. Pathol. Lab. Med. 2013, 137:632-636.
250. Matsumoto S., Nabeshima K., Kamei T., Hiroshima K., Kawahara K., Hata S., Marukawa K., Matsuno Y., Taguchi K., Tsujimura T. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol. 2013, 121:415-422.
251. Cheng J.Q., Lee W.C., Klein M.A., Cheng G.Z., Jhanwar S.C., Testa J.R. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosom. Cancer 1999, 24:238-242.
252. Deguen B., Goutebroze L., Giovannini M., Boisson C., van der Neut R., Jaurand M.C., Thomas G. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int. J. Cancer 1998, 77:554-560.